Valuation: Medivir AB

Market Cap 967M 98.46M 88.18M 81.11M 73.49M 137M 9.35B 140M 388M 4.92B 370M 362M 15.51B P/E 2026 *
-11.9x
P/E 2027 * -10.3x
Enterprise Value 749M 76.27M 68.31M 62.83M 56.93M 106M 7.24B 108M 301M 3.81B 286M 280M 12.01B EV / Sales 2026 *
174x
EV / Sales 2027 * 5.7x
Free-Float
64.22%
Yield 2026 *
-
Yield 2027 * -
1 day-3.73%
1 week+4.03%
1 month-5.37%
3 months-14.84%
6 months-18.59%
Current year+278.97%
1 week 1.47
Extreme 1.47
1.64
1 month 1.42
Extreme 1.416
1.78
Current year 0.39
Extreme 0.392
2.88
1 year 0.34
Extreme 0.34
2.88
3 years 0.34
Extreme 0.34
7.99
5 years 0.34
Extreme 0.34
11.84
10 years 0.34
Extreme 0.34
102
Manager TitleAgeSince
Chief Executive Officer 55 2022-01-23
Director of Finance/CFO - 2026-03-22
Chief Tech/Sci/R&D Officer 60 2023-02-19
Director TitleAgeSince
Chairman 76 2021-05-04
Director/Board Member 70 2018-05-02
Director/Board Member 47 2021-05-04
Date Insider Type Main position Quantity % Market Cap. Importance
7/27/26
Hallberg Management AB
BuyCompany 6,097,560 0.9868%
6/18/26 Buy

Chief Financial Officer

18,000 0.0033%
12/5/25 Buy 90,000 0.0802%
Change 5-day change 1-year change 3-year change Capi.($)
-3.73%+4.03%+187.04%-77.95% 98.46M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.07%+7.19%+61.52%+167.69% 39.44B
Weighted average by Cap. +0.18%+5.44%+48.03%+176.61%

Financials

2026 *2027 *
Net sales 4.3M 438K 392K 361K 327K 611K 41.56M 622K 1.73M 21.86M 1.64M 1.61M 68.94M 148M 15.12M 13.54M 12.45M 11.28M 21.09M 1.44B 21.49M 59.61M 755M 56.73M 55.52M 2.38B
Net income -69.1M -7.03M -6.3M -5.79M -5.25M -9.81M -668M -10M -27.74M -351M -26.4M -25.84M -1.11B 125M 12.77M 11.44M 10.52M 9.53M 17.82M 1.21B 18.15M 50.36M 638M 47.92M 46.9M 2.01B
Net Debt -218M -22.19M -19.87M -18.28M -16.56M -30.96M -2.11B -31.54M -87.51M -1.11B -83.28M -81.51M -3.5B -121M -12.32M -11.03M -10.15M -9.19M -17.19M -1.17B -17.51M -48.57M -615M -46.22M -45.24M -1.94B
Projected Income Statement - Annual - Medivir AB
Logo Medivir AB
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Employees
6
Date Price Change Volume
26-10-30 SEK 1.550 -3.73% 596,280
26-10-29 SEK 1.610 +0.12% 1,168,035
26-10-28 SEK 1.608 +2.68% 896,038
26-10-27 SEK 1.566 +1.82% 996,029
26-10-26 SEK 1.538 +3.22% 831,194
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Medivir AB

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Medivir AB
  1. Stock Market
  2. Stocks
  3. MVIR B Stock